On the basis of the strong in vitro synergy on the ovarian cancer cell line OVCAR-3, we chose this model for in vivo evaluation of the combinations of MSLN-TTC with the PARPi and the ATRi. The gene discussed is MSLN; the disease is ovarian cancer.